$DOCS

Cabral Timothy S sold $293K of DOCS

Cabral Timothy S sold 7,500 shares of Doximity, Inc. (DOCS) at $39.11 ($0.29M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cabral Timothy S
Published Aug 11, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DOCS
Neutral
high confidence
Mentioned
$DOCS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DOCSNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director under a pre-arranged 10b5-1 plan, which generally reduces interpretive weight for near-term price direction.

02

Market read

Traders may note the sale for positioning and sentiment, but there is no new operational, financial, or regulatory catalyst for DOCS in the text.

03

What to watch

The article does not state whether the sale was part of a larger scheduled program, nor does it provide option exercises, purchases, or changes in other insiders’ activity.

Relevance 3/10Novelty 2/10Timing: filed Aug 11, covering a sale executed Aug 7

Background

The article is a SEC Form 4 insider transaction disclosure for Doximity, Inc. (DOCS).

Company-level read

Ticker impact

$DOCSNeutralHigh confidence
Context

Doximity director Timothy S Cabral sold 7,500 shares in an open-market transaction on Aug 7 at $39.11, per Form 4.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan and provides only a routine sale size and price, with no accompanying company-specific news.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with periods of weaker internal conviction, so traders may watch for follow-on sales.

Key entities

  • Doximity, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Timothy S Cabral

    Director who sold 7,500 shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Doximity's former chief revenue officer, Paul Jorgensen, was ordered to pay $490,000 to the SEC for insider trading. He sold shares based on nonpublic information ahead of negative earnings announcements, avoiding losses and making $2.2 million in profits. Jorgensen was also sentenced to 26 months in prison and ordered to forfeit $2.5 million in a parallel criminal case.

$DOCSMed

Doximity stock falls as Freedom Capital cuts to hold

Doximity Inc (DOCS) shares dropped 5.6% after Freedom Capital downgraded it to Hold, raising its price target to $27. The company beat Q1 estimates, increased full-year revenue guidance, but lowered EBITDA outlook due to AI investment. Freedom Capital noted strong AI search traction but margin concerns and core business softening.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 2027 revenue of $156.6 million, up 7% year over year, and adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million. It said AI workflow and scribe usage grew, repurchased $91.6 million of stock, and ended June 30 with $688 million in cash and marketable securities.

$DOCSMedAI 8/10

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.

$DOCSMed

Doximity Stock Surges in Overnight Trading as Chief Executive Highlights High-Margin AI Tool

Doximity (DOCS) shares jumped in overnight trading after CEO Jeffrey Tangney said the company’s new AI search tool generates over 10 times the revenue versus its operating cost. The stock later closed up 33% on Friday. Doximity reported Q1 revenue of $156.6M and adjusted EBITDA of $74.8M, and raised full-year guidance to $671M-$681M. Wells Fargo later downgraded to underweight.